U.S. Stock Market Midday Update: Solana down 18.28%

U.S. Stock Market Midday Update

Solana fell 18.28%, with increased trading volume. According to recent important news:

1. On October 16, Solana led with $6.16 billion in trading volume on decentralized exchanges (DEX), indicating strong market demand and activity, driving price fluctuations; source: Cointelegraph.

2. On October 15, Solmate Infrastructure purchased $50 million worth of SOL at a discount, demonstrating institutional confidence in Solana, which may positively impact market sentiment; source: Blockchain.

3. On October 13, CME Group launched Solana options, increasing market interest and trading activity for the asset, potentially leading to price volatility; source: ARK Invest. The cryptocurrency market is experiencing increased volatility, and risks should be monitored.

Stocks with High Trading Volume in the Industry

Abbott fell 0.30%, with a trading volume of $312 million. According to recent key news:

1. On October 15, Abbott reported third-quarter revenue slightly below expectations, primarily due to weakness in its diagnostics and nutrition businesses. The company lowered its full-year earnings per share forecast, with the stock price dropping nearly 3% in pre-market trading. Third-quarter revenue was $11.37 billion, below the expected $11.4 billion. Diagnostics sales fell 6.6% to $2.25 billion, below the expected $2.29 billion. Medical device sales grew 14.8% to $5.45 billion. Source: Zhitong Finance.

2. On October 15, Abbott announced third-quarter results, with revenue of $11.37 billion, slightly below the average analyst expectation of $11.4 billion; earnings per share were $1.30, in line with expectations. Abbott expects full-year earnings per share to be between $5.12 and $5.18, previously expected to be between $5.10 and $5.20. Source: Gelonghui.

3. On October 15, Abbott reported third-quarter results, with revenue slightly below market expectations. The company stated that it currently expects adjusted annual earnings per share to be between $5.12 and $5.18, while the previous expectation was between $5.10 and $5.20. Source: Abbott. The overall performance of the medical device industry remains stable, with attention to policy changes.

Becton Dickinson fell 2.48%. According to recent key news:

1. On October 16, Becton Dickinson announced preliminary revenue forecasts for the fourth quarter and the full year of fiscal year 2025 that were below market expectations. The company expects fourth-quarter revenue to be $5.9 billion and full-year revenue to be $21.8 billion, both below market expectations of $5.91 billion and $21.86 billion, respectively. This news caused the stock price to drop about 6% in after-hours trading.

2. On October 16, Becton Dickinson announced that its Executive Vice President and Chief Financial Officer Chris DelOrefice will leave the company on December 5, and the company appointed Vitor Roque as interim Chief Financial Officer This news has raised concerns in the market about the stability of the company's management, further putting pressure on the stock price.

3. On October 16, Becton Dickinson celebrated the 65th anniversary of its operations at the Broken Bow plant in Nebraska. Although this milestone demonstrates the stability of the company's manufacturing capabilities, it failed to offset the impact of other negative news on the stock price. The medical technology industry has shown stable performance recently, and attention should be paid to the impact of macroeconomic data on the industry.

Boston Scientific rose 1.12%. According to recent important news:

1. On October 15, the procurement of urological surgical consumables entered the preparation stage. As a market-leading brand, Boston Scientific may face market share adjustments. A notice from the Chongqing Medical Security Bureau indicates that the collective procurement among 26 provincial alliances will bring structural adjustments and opportunities for domestic substitution, affecting Boston Scientific's market position.

2. On October 14, analysts expect Boston Scientific to exceed expectations in achieving its quarterly sales targets, with projected sales of $4.96 billion and an annual sales target of $20 billion. The market holds an optimistic view of its performance, driving the stock price up.

3. On October 13, domestic companies' technological breakthroughs and market share increases in the field of urological intervention may pose challenges to Boston Scientific's market share. Domestic companies are gradually achieving substitution through collective procurement and technological innovation, leading to competitive pressure from market structure adjustments. The market structure of urological consumables is adjusting, with accelerated domestic substitution.

Stocks ranked among the top in industry market capitalization

Intuitive Surgical rose 0.72%. According to recent important news:

1. On October 16, market analysts pointed out that although Intuitive Surgical's business performance is outstanding, its stock is considered to have a single business model, which may lead investors to seek more diversified alternatives. This view may exert some pressure on the stock price, causing investors to reassess their portfolios.

2. On October 15, Intuitive Surgical's stock trading price has fallen about 30% from its 52-week high. This information may trigger a re-examination of its valuation in the market, leading to stock price fluctuations.

3. On October 14, the healthcare sector as a whole performed poorly, lagging behind the S&P 500 index by about 22% over the past 12 months. This industry trend may negatively impact Intuitive Surgical's stock price. The healthcare sector is underperforming, putting pressure on valuations